180 related articles for article (PubMed ID: 32971984)
1. Targeted-Alpha-Therapy Combining Astatine-211 and anti-CD138 Antibody in A Preclinical Syngeneic Mouse Model of Multiple Myeloma Minimal Residual Disease.
Gouard S; Maurel C; Marionneau-Lambot S; Dansette D; Bailly C; Guérard F; Chouin N; Haddad F; Alliot C; Gaschet J; Eychenne R; Kraeber-Bodéré F; Chérel M
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32971984
[TBL] [Abstract][Full Text] [Related]
2. Single-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical Model.
Fichou N; Gouard S; Maurel C; Barbet J; Ferrer L; Morgenstern A; Bruchertseifer F; Faivre-Chauvet A; Bigot-Corbel E; Davodeau F; Gaschet J; Chérel M
Front Med (Lausanne); 2015; 2():76. PubMed ID: 26582128
[TBL] [Abstract][Full Text] [Related]
3. 213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma.
Chérel M; Gouard S; Gaschet J; Saï-Maurel C; Bruchertseifer F; Morgenstern A; Bourgeois M; Gestin JF; Bodéré FK; Barbet J; Moreau P; Davodeau F
J Nucl Med; 2013 Sep; 54(9):1597-604. PubMed ID: 24003167
[TBL] [Abstract][Full Text] [Related]
4. What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between
Bailly C; Gouard S; Guérard F; Chalopin B; Carlier T; Faivre-Chauvet A; Remaud-Le Saëc P; Bourgeois M; Chouin N; Rbah-Vidal L; Tripier R; Haddad F; Kraeber-Bodéré F; Bodet-Milin C; Chérel M
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137758
[TBL] [Abstract][Full Text] [Related]
5. Comparative analysis of multiple myeloma treatment by CD138 antigen targeting with bismuth-213 and Melphalan chemotherapy.
Gouard S; Pallardy A; Gaschet J; Faivre-Chauvet A; Bruchertseifer F; Morgenstern A; Maurel C; Matous E; Kraeber-Bodéré F; Davodeau F; Chérel M
Nucl Med Biol; 2014 May; 41 Suppl():e30-5. PubMed ID: 24759272
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Immuno-PET of CD138 and PET imaging with
Bailly C; Gouard S; Lacombe M; Remaud-Le Saëc P; Chalopin B; Bourgeois M; Chouin N; Tripier R; Halime Z; Haddad F; Faivre-Chauvet A; Kraeber-Bodéré F; Chérel M; Bodet-Milin C
Oncotarget; 2018 Feb; 9(10):9061-9072. PubMed ID: 29507674
[TBL] [Abstract][Full Text] [Related]
7. Vascular-targeted radioimmunotherapy with the alpha-particle emitter 211At.
Kennel SJ; Mirzadeh S; Eckelman WC; Waldmann TA; Garmestani K; Yordanov AT; Stabin MG; Brechbiel MW
Radiat Res; 2002 Jun; 157(6):633-41. PubMed ID: 12005541
[TBL] [Abstract][Full Text] [Related]
8. TE1PA as Innovating Chelator for
Navarro AS; Le Bihan T; Le Saëc P; Bris NL; Bailly C; Saï-Maurel C; Bourgeois M; Chérel M; Tripier R; Faivre-Chauvet A
Bioconjug Chem; 2019 Sep; 30(9):2393-2403. PubMed ID: 31386357
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Evaluation of a
Métivier C; Le Saëc P; Gaschet J; Chauvet C; Marionneau-Lambot S; Hofgaard PO; Bogen B; Pineau J; Le Bris N; Tripier R; Alliot C; Haddad F; Chérel M; Chouin N; Faivre-Chauvet A; Rbah-Vidal L
Pharmaceutics; 2023 Jun; 15(7):. PubMed ID: 37514004
[TBL] [Abstract][Full Text] [Related]
10. The pre-clinical characterization of an alpha-emitting sigma-2 receptor targeted radiotherapeutic.
Makvandi M; Lieberman BP; LeGeyt B; Hou C; Mankoff DA; Mach RH; Pryma DA
Nucl Med Biol; 2016 Jan; 43(1):35-41. PubMed ID: 26702785
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice.
Palm S; Bäck T; Claesson I; Danielsson A; Elgqvist J; Frost S; Hultborn R; Jensen H; Lindegren S; Jacobsson L
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):572-9. PubMed ID: 17869670
[TBL] [Abstract][Full Text] [Related]
12. Radiopharmaceutical therapy of 5T33 murine myeloma by sequential treatment with samarium-153 ethylenediaminetetramethylene phosphonate, melphalan, and bone marrow transplantation.
Turner JH; Claringbold PG; Manning LS; O'Donoghue HL; Berger JD; Glancy RJ
J Natl Cancer Inst; 1993 Sep; 85(18):1508-13. PubMed ID: 8360933
[TBL] [Abstract][Full Text] [Related]
13. [Comparison and analysis of minimal residual disease in multiple myeloma patients detected by 4-color and 8-color fluorescence antibody panels].
Wang YZ; Lu J; Hao L; Chang Y; He LL; Huang XJ; Liu YR
Zhonghua Xue Ye Xue Za Zhi; 2017 Apr; 38(4):272-278. PubMed ID: 28468086
[No Abstract] [Full Text] [Related]
14. The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide Therapy.
Puttemans J; Stijlemans B; Keyaerts M; Vander Meeren S; Renmans W; Fostier K; Debie P; Hanssens H; Rodak M; Pruszynski M; De Veirman K; Vanderkerken K; Lahoutte T; Morgenstern A; Bruchertseifer F; Devoogdt N; D'Huyvetter M
Mol Cancer Ther; 2022 Jan; 21(1):159-169. PubMed ID: 34667109
[TBL] [Abstract][Full Text] [Related]
15. Targeted cancer cell ablation in mice by an α-particle-emitting astatine-211-labeled antibody against major histocompatibility complex class I chain-related protein A and B.
Li HK; Hasegawa S; Nakajima NI; Morokoshi Y; Minegishi K; Nagatsu K
Biochem Biophys Res Commun; 2018 Dec; 506(4):1078-1084. PubMed ID: 30409432
[TBL] [Abstract][Full Text] [Related]
16. Targeted immunotherapy using anti-CD138-interferon α fusion proteins and bortezomib results in synergistic protection against multiple myeloma.
Vasuthasawat A; Yoo EM; Trinh KR; Lichtenstein A; Timmerman JM; Morrison SL
MAbs; 2016 Oct; 8(7):1386-1397. PubMed ID: 27362935
[TBL] [Abstract][Full Text] [Related]
17. The development of a [211AT]-astatinated endoradiotherapeutic drug: part IV--late radiation effects.
Brown I; Mitchell JS
Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1177-83. PubMed ID: 9539575
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapy for multiple myeloma: an overview on CD138-based strategies.
Riccardi F; Tangredi C; Dal Bo M; Toffoli G
Front Oncol; 2024; 14():1370854. PubMed ID: 38655136
[TBL] [Abstract][Full Text] [Related]
19. Alpha-particle radiotherapy with 211At-labeled monodisperse polymer particles, 211At-labeled IgG proteins, and free 211At in a murine intraperitoneal tumor model.
Larsen RH; Hoff P; Vergote IB; Bruland OS; Aas M; De Vos L; Nustad K
Gynecol Oncol; 1995 Apr; 57(1):9-15. PubMed ID: 7705707
[TBL] [Abstract][Full Text] [Related]
20. Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma.
Palumbo A; Sonneveld P
Expert Rev Hematol; 2015 Aug; 8(4):481-91. PubMed ID: 26070331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
